Conferences & Events

Best of WCLC 2018: San Francisco


The program condenses the timeliest scientific and educational topics from multiple disciplines. Presented by regional teams recruited from multiple disciplines, the event brings the top abstracts as chosen by the experts on the 19th WCLC Scientific Committee to professionals engaged in the diagnosis and treatment of lung cancer and related malignancies in a concise presentation.


To register for this event, please click the following link or the button below. General admission is $50.00 per registrant. Complimentary tickets are available for IASLC, ANCO and academic institution affiliates (UCD, UCSF, Stanford).



This CME live activity was designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physician assistants.


After attending this session, participants will:

  • Identify effective global lung cancer prevention strategies.
  • Improve their ability to participate in tobacco control and smoking cessation programs.
  • Recognize the current approaches and strategies for early detection and screening of lung cancer.
  • Demonstrate the best methods to implement multi-disciplinary tumor boards into community practices.
  • Examine evidence-based therapeutic regimens for early stage and locally advanced NSCLC.
  • Distinguish evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics.
  • Define best practices regarding the application of targeted therapies for metastatic NSCLC in frontline and then subsequent settings following acquired resistance to the targeted therapy.
  • Describe current and emerging immunotherapy strategies in the context of clinical trials findings and patient selection in metastatic NSCLC.
  • Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen.
  • Review the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in non-academic settings.

This activity was Commercially Supported: IASLC expresses appreciation to Bristol-Myers Squibb, Pfizer, AstraZeneca, Boehringer Ingelheim, Lilly, Merck and Genentech for their support of this educational activity by providing unrestricted educational grants.


Best of WCLC San Francisco 2018
Saturday, November 17, 2018
Intercontinental San Francisco
888 Howard Street, 5th Floor
San Francisco, California 94103
Hotel's Official Website


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The content has been reviewed for conformity with ACCME Essentials, Policies, and Standards for Commercial Support.


An evaluation link will be email to the email you’ve provided. Upon completion of the electronic evaluation link the CME Certificate will be ready for you to print or save for your records. This information is used not only to evaluate the present activity, but also to plan for future programs.